Alpharadin may change standard of care for prostate cancer patients with bone mets

We recently attended the 2011 European Multidisciplinary Cancer Congress in Stockholm. Paradigm shifting data in breast cancer and advanced prostate cancer were presented at what turned out to be an excellent meeting in a charming, if expensive, city.

Sally Church (@MaverickNY) live tweeted several sessions from the meeting and was name the “Top Twitter Influencer” for the #EMCC2011 hashtag. You can catch up with the tweets fron ECCO ESMO ESTRO 2011 on Pharma Strategy Blog.

Pieter Droppert (@3NT) has written several posts on biotech strategy blog about the exciting data for radium-223 (Alpharadin) in advanced prostate cancer that was presented in Stockholm.

He also produced a video of the media briefing by Dr Chris Parker from the Royal Marsden Hospital where the ALSYMPCA phase 3 trial results were reviewed.  It is well worth watching!

http://youtu.be/_oAJ1fU0PT4

Please contact us if you would like to learn more about the fast moving Prostate Cancer market and how pharma marketing strategy may be impacted by the new products in development such as radium-223 (Alpharadin), that is on fast track for FDA approval in 2012.

, , , , , , , , , , , , , , , ,

error: Content is protected !!